{"product_id":"retaklik-retatrutide-30mg-price-uae","title":"Retaklik Retatrutide 30mg UAE – Research \u0026 Product Information","description":"\u003ch2\u003eDescription\u003c\/h2\u003e\u003cp\u003eRetaklik Retatrutide 30mg UAE is a product listing associated with retatrutide, an investigational compound being studied in clinical research. Retatrutide is also known by the development code LY3437943 and is being investigated as a triple receptor agonist involving the GIP, GLP-1 and glucagon pathways.\u003c\/p\u003e\u003cp\u003eRetatrutide has received significant scientific attention because researchers are studying whether simultaneous activity across these three pathways can influence body weight, glucose-related outcomes and other metabolic measures. ClinicalTrials.gov continues to list active retatrutide development programs, including Phase 3 and Phase 3b studies.\u003c\/p\u003e\u003cp\u003eThe Pureness X page currently lists the product as Retatrutide 30mg UAE with a displayed price of AED 800. This is a store listing price and should not be interpreted as an official UAE medicine price.\u003c\/p\u003e\u003cp\u003eMost importantly, retatrutide should not be confused with an approved prescription medicine. UAE health authorities have warned about unauthorized retatrutide products, while retatrutide remains under clinical development.\u003c\/p\u003e\u003ch2\u003eQuick Product Overview\u003c\/h2\u003e\u003cp\u003eProduct Information\u003c\/p\u003e\u003cp\u003eDetails\u003c\/p\u003e\u003cp\u003eListed product name\u003c\/p\u003e\u003cp\u003eRetaklik Retatrutide 30mg\u003c\/p\u003e\u003cp\u003eListed strength\u003c\/p\u003e\u003cp\u003e30 mg\u003c\/p\u003e\u003cp\u003eActive research compound\u003c\/p\u003e\u003cp\u003eRetatrutide\u003c\/p\u003e\u003cp\u003eDevelopment code\u003c\/p\u003e\u003cp\u003eLY3437943\u003c\/p\u003e\u003cp\u003eResearch mechanism\u003c\/p\u003e\u003cp\u003eGIP + GLP-1 + glucagon\u003c\/p\u003e\u003cp\u003eResearch classification\u003c\/p\u003e\u003cp\u003eInvestigational\u003c\/p\u003e\u003cp\u003eListed UAE price\u003c\/p\u003e\u003cp\u003eAED 800\u003c\/p\u003e\u003cp\u003ePrimary topic\u003c\/p\u003e\u003cp\u003eClinical and scientific research\u003c\/p\u003e\u003cp\u003eThe product name, stated strength and displayed price above reflect the current Pureness X listing.\u003c\/p\u003e\u003ch2\u003eWhat Is Retatrutide?\u003c\/h2\u003e\u003cp\u003eRetatrutide, also known as LY3437943, is an investigational molecule being developed by Eli Lilly.\u003c\/p\u003e\u003cp\u003eIts main scientific feature is its activity across three receptor pathways:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGLP-1 receptor\u003c\/li\u003e\n\u003cli\u003eGIP receptor\u003c\/li\u003e\n\u003cli\u003eGlucagon receptor\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eBecause of this combination, retatrutide is commonly described in scientific literature as a triple agonist.\u003c\/p\u003e\u003cp\u003eThis distinguishes it from medicines or investigational compounds that target only one receptor pathway.\u003c\/p\u003e\u003cp\u003eResearchers are studying the combined effects of these pathways because they are involved in appetite regulation, glucose metabolism and energy balance.\u003c\/p\u003e\u003ch2\u003eWhat Does the Triple-Agonist Mechanism Mean?\u003c\/h2\u003e\u003cp\u003eThe term triple agonist refers to activity at three hormone receptor systems.\u003c\/p\u003e\u003ch3\u003eGLP-1 Pathway\u003c\/h3\u003e\u003cp\u003eGLP-1 signalling is involved in appetite regulation, satiety and glucose-related processes.\u003c\/p\u003e\u003ch3\u003eGIP Pathway\u003c\/h3\u003e\u003cp\u003eGIP is involved in glucose-dependent insulin signalling and broader metabolic processes.\u003c\/p\u003e\u003ch3\u003eGlucagon Pathway\u003c\/h3\u003e\u003cp\u003eGlucagon is involved in energy metabolism and regulation of stored energy.\u003c\/p\u003e\u003cp\u003eRetatrutide is being investigated because researchers want to understand whether activating these pathways together can produce clinically meaningful metabolic effects.\u003c\/p\u003e\u003cp\u003eThe mechanism itself does not establish that retatrutide is approved or appropriate for individual treatment.\u003c\/p\u003e\u003ch2\u003eRetatrutide and Clinical Research\u003c\/h2\u003e\u003cp\u003eRetatrutide has progressed considerably through clinical development.\u003c\/p\u003e\u003cp\u003eClinicalTrials.gov currently lists studies evaluating retatrutide in people with obesity or overweight and other research populations. For example, TRIUMPH-6 is a Phase 3b study investigating maintenance of weight reduction, while TRIUMPH-8 is a Phase 3b study evaluating efficacy and safety in people with obesity or overweight.\u003c\/p\u003e\u003cp\u003eAnother Phase 3b study, TRIUMPH-9, is investigating different dose-escalation approaches in participants without type 2 diabetes who have obesity or overweight.\u003c\/p\u003e\u003cp\u003eThese studies demonstrate ongoing scientific development, but clinical development should not be confused with regulatory approval.\u003c\/p\u003e\u003ch2\u003eRetatrutide and Weight-Management Research\u003c\/h2\u003e\u003cp\u003eWeight management is one of the major research areas involving retatrutide.\u003c\/p\u003e\u003cp\u003ePublished clinical research has investigated changes in body weight, body composition and metabolic outcomes. Research findings can provide information about the potential of an investigational compound, but results from clinical trials cannot guarantee the same outcome for an individual.\u003c\/p\u003e\u003cp\u003eThe appropriate interpretation of clinical-trial results depends on:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eStudy population\u003c\/li\u003e\n\u003cli\u003eDose and treatment schedule\u003c\/li\u003e\n\u003cli\u003eStudy duration\u003c\/li\u003e\n\u003cli\u003eTrial design\u003c\/li\u003e\n\u003cli\u003eSafety findings\u003c\/li\u003e\n\u003cli\u003eStatistical analysis\u003c\/li\u003e\n\u003cli\u003eRegulatory review\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eFor this reason, online product descriptions should not turn clinical-trial findings into promises about individual weight loss.\u003c\/p\u003e\u003ch2\u003eRetatrutide vs GLP-1 Research\u003c\/h2\u003e\u003cp\u003eRetatrutide is sometimes described as a next-generation metabolic compound because it acts on three receptor pathways rather than one.\u003c\/p\u003e\u003cp\u003eResearch approach\u003c\/p\u003e\u003cp\u003eMain receptor pathways\u003c\/p\u003e\u003cp\u003eGLP-1 agonist\u003c\/p\u003e\u003cp\u003eGLP-1\u003c\/p\u003e\u003cp\u003eGLP-1\/GIP dual agonist\u003c\/p\u003e\u003cp\u003eGLP-1 + GIP\u003c\/p\u003e\u003cp\u003eRetatrutide\u003c\/p\u003e\u003cp\u003eGLP-1 + GIP + glucagon\u003c\/p\u003e\u003cp\u003eThis difference in receptor activity is one of the main scientific reasons retatrutide is being investigated.\u003c\/p\u003e\u003cp\u003eHowever, mechanism alone should not be used to claim that retatrutide is automatically better than approved medicines.\u003c\/p\u003e\u003ch2\u003eWhat Is LY3437943?\u003c\/h2\u003e\u003cp\u003eLY3437943 is the development code associated with retatrutide.\u003c\/p\u003e\u003cp\u003eWhen researching retatrutide online, using both terms can be useful because scientific papers and clinical-trial records may use LY3437943 instead of the name retatrutide.\u003c\/p\u003e\u003cp\u003eFor research purposes, useful search terms include:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eRetatrutide\u003c\/li\u003e\n\u003cli\u003eLY3437943\u003c\/li\u003e\n\u003cli\u003eRetatrutide clinical trial\u003c\/li\u003e\n\u003cli\u003eRetatrutide Phase 3\u003c\/li\u003e\n\u003cli\u003eRetatrutide triple agonist\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eClinicalTrials.gov uses both retatrutide and LY3437943 in its trial information.\u003c\/p\u003e\u003ch2\u003eRetaklik Retatrutide 30mg Product Information\u003c\/h2\u003e\u003cp\u003eThe current Pureness X listing identifies the product as Retatrutide 30mg UAE and displays a price of AED 800.\u003c\/p\u003e\u003cp\u003eFor any research-product listing, users should independently verify relevant documentation rather than relying solely on a product-page description.\u003c\/p\u003e\u003cp\u003eImportant information to verify may include:\u003c\/p\u003e\u003ch3\u003eProduct identity\u003c\/h3\u003e\u003cp\u003eConfirm the stated compound name and strength.\u003c\/p\u003e\u003ch3\u003eBatch information\u003c\/h3\u003e\u003cp\u003eCheck whether a specific batch or lot number is provided.\u003c\/p\u003e\u003ch3\u003eLaboratory documentation\u003c\/h3\u003e\u003cp\u003eWhere available, review batch-specific laboratory documentation.\u003c\/p\u003e\u003ch3\u003eCertificate of Analysis\u003c\/h3\u003e\u003cp\u003eA COA should be evaluated for the actual batch rather than treated as proof that every product from a supplier has the same characteristics.\u003c\/p\u003e\u003ch3\u003eSupplier information\u003c\/h3\u003e\u003cp\u003eVerify the identity and provenance of the supplier.\u003c\/p\u003e\u003ch3\u003eRegulatory status\u003c\/h3\u003e\u003cp\u003eCheck the current requirements of the relevant UAE health authority.\u003c\/p\u003e\u003ch2\u003eRetatrutide UAE Regulatory Status\u003c\/h2\u003e\u003cp\u003eThis is one of the most important sections for this page.\u003c\/p\u003e\u003cp\u003eThe UAE Department of Health issued a March 2026 alert warning the public and healthcare\/pharmaceutical sector about unauthorized retatrutide products. The alert states that retatrutide remains under clinical development and that there is no authorized supply or legitimate distribution in global markets.\u003c\/p\u003e\u003cp\u003eTherefore, an online listing should not be presented as evidence that retatrutide is an approved UAE medicine.\u003c\/p\u003e\u003ch3\u003eImportant distinction\u003c\/h3\u003e\u003cp\u003eOnline listing ≠ regulatory approval\u003c\/p\u003e\u003cp\u003eClinical trial ≠ public authorization\u003c\/p\u003e\u003cp\u003eProduct price ≠ official UAE medicine price\u003c\/p\u003e\u003cp\u003eProduct claim ≠ laboratory verification\u003c\/p\u003e\u003cp\u003eThis distinction is particularly important for anyone searching for Retatrutide 30mg UAE or related terms.\u003c\/p\u003e\u003ch2\u003eIs Retatrutide Approved in the UAE?\u003c\/h2\u003e\u003cp\u003eCurrent UAE health-authority information indicates that retatrutide is not an authorized medicine for routine public use. The Department of Health has specifically warned against unauthorized retatrutide products.\u003c\/p\u003e\u003cp\u003eTherefore, this page should not describe retatrutide as an approved UAE medication or claim that it is routinely available through UAE pharmacies.\u003c\/p\u003e\u003ch2\u003eRetatrutide Safety Research\u003c\/h2\u003e\u003cp\u003eSafety is an essential part of the ongoing clinical-development process.\u003c\/p\u003e\u003cp\u003eClinical trials are designed to investigate both potential benefits and adverse events in controlled populations.\u003c\/p\u003e\u003cp\u003eResearchers evaluate factors such as:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGastrointestinal adverse events\u003c\/li\u003e\n\u003cli\u003eChanges in metabolic parameters\u003c\/li\u003e\n\u003cli\u003eCardiovascular measurements\u003c\/li\u003e\n\u003cli\u003eTolerability\u003c\/li\u003e\n\u003cli\u003eTreatment discontinuation\u003c\/li\u003e\n\u003cli\u003eLonger-term safety\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eBecause retatrutide remains investigational, its complete safety profile continues to be evaluated through clinical research.\u003c\/p\u003e\u003cp\u003eFor that reason, this product page should not provide personalized dosing or injection instructions.\u003c\/p\u003e\u003ch2\u003eWhy Clinical Trials Matter\u003c\/h2\u003e\u003cp\u003eClinical trials help researchers answer questions that cannot be answered through product descriptions alone.\u003c\/p\u003e\u003cp\u003eThey evaluate:\u003c\/p\u003e\u003col\u003e\n\u003cli\u003eEfficacy — whether a compound produces meaningful effects.\u003c\/li\u003e\n\u003cli\u003eSafety — what adverse events occur.\u003c\/li\u003e\n\u003cli\u003eDose response — how outcomes vary across research doses.\u003c\/li\u003e\n\u003cli\u003ePopulation differences — how different groups respond.\u003c\/li\u003e\n\u003cli\u003eLonger-term outcomes — what happens with extended exposure.\u003c\/li\u003e\n\u003cli\u003eRegulatory evidence — whether the total evidence supports potential approval.\u003c\/li\u003e\n\u003c\/ol\u003e\u003cp\u003eClinicalTrials.gov continues to list retatrutide studies across different phases and research populations.\u003c\/p\u003e\u003ch2\u003eWhat Should Researchers Check Before Relying on a Product Listing?\u003c\/h2\u003e\u003cp\u003eAnyone researching an online peptide or investigational-compound listing should consider several verification points.\u003c\/p\u003e\u003ch3\u003e1. Compound identity\u003c\/h3\u003e\u003cp\u003eCheck whether the claimed compound is clearly identified.\u003c\/p\u003e\u003ch3\u003e2. Batch information\u003c\/h3\u003e\u003cp\u003eLook for a specific lot or batch number.\u003c\/p\u003e\u003ch3\u003e3. Testing documentation\u003c\/h3\u003e\u003cp\u003eReview available laboratory documentation and understand exactly what was tested.\u003c\/p\u003e\u003ch3\u003e4. Certificate of Analysis\u003c\/h3\u003e\u003cp\u003eCheck whether the documentation relates to the actual batch.\u003c\/p\u003e\u003ch3\u003e5. Storage information\u003c\/h3\u003e\u003cp\u003eVerify storage requirements against reliable product documentation.\u003c\/p\u003e\u003ch3\u003e6. Regulatory status\u003c\/h3\u003e\u003cp\u003eConfirm whether the compound is authorized for the intended use in the relevant jurisdiction.\u003c\/p\u003e\u003ch3\u003e7. Intended use\u003c\/h3\u003e\u003cp\u003eDo not assume that a research listing is equivalent to an approved medicine.\u003c\/p\u003e\u003ch2\u003eRetatrutide 30mg UAE Price Information\u003c\/h2\u003e\u003cp\u003eThe Pureness X page currently displays AED 800 for the listed product.\u003c\/p\u003e\u003cp\u003eHowever, this should be described as an online product listing price, not an official UAE medicine price.\u003c\/p\u003e\u003cp\u003eBecause retatrutide is not authorized for routine public use in the UAE, online prices should not be interpreted as regulated pharmacy pricing. The UAE Department of Health's warning is particularly relevant when evaluating online retatrutide claims.\u003c\/p\u003e\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\u003ch3\u003eWhat is Retaklik Retatrutide 30mg?\u003c\/h3\u003e\u003cp\u003eThe Pureness X page lists Retaklik Retatrutide 30mg as a 30 mg retatrutide product. Retatrutide itself is an investigational compound being studied in clinical research.\u003c\/p\u003e\u003ch3\u003eWhat is retatrutide?\u003c\/h3\u003e\u003cp\u003eRetatrutide is an investigational compound also known as LY3437943. It is being studied as a triple receptor agonist involving GLP-1, GIP and glucagon pathways.\u003c\/p\u003e\u003ch3\u003eWhat is LY3437943?\u003c\/h3\u003e\u003cp\u003eLY3437943 is the development code associated with retatrutide and is used in clinical-trial and scientific research records.\u003c\/p\u003e\u003ch3\u003eIs retatrutide approved in the UAE?\u003c\/h3\u003e\u003cp\u003eNo. UAE health authorities have warned about unauthorized retatrutide products and state that the compound remains under clinical development.\u003c\/p\u003e\u003ch3\u003eWhat is the listed price of Retaklik Retatrutide 30mg?\u003c\/h3\u003e\u003cp\u003eThe Pureness X page currently displays AED 800. This is an online listing price, not an official regulated UAE medicine price.\u003c\/p\u003e\u003ch3\u003eIs retatrutide a GLP-1-only compound?\u003c\/h3\u003e\u003cp\u003eNo. Retatrutide is being investigated as a triple agonist involving GLP-1, GIP and glucagon receptors.\u003c\/p\u003e\u003ch3\u003eWhat is Retatrutide Phase 3?\u003c\/h3\u003e\u003cp\u003ePhase 3 refers to later-stage clinical research designed to evaluate efficacy and safety in larger populations. Retatrutide has ongoing Phase 3\/3b clinical development programs.\u003c\/p\u003e\u003ch2\u003eFinal Thoughts\u003c\/h2\u003e\u003cp\u003eRetatrutide has become an important subject in metabolic-health research because of its triple-receptor mechanism involving GLP-1, GIP and glucagon.\u003c\/p\u003e\u003cp\u003eFor people researching Retaklik Retatrutide 30mg UAE, the most important issue is to distinguish between an online product listing and an approved medicine.\u003c\/p\u003e\u003cp\u003eRetatrutide remains an investigational compound, and UAE authorities have issued a warning regarding unauthorized retatrutide products.\u003c\/p\u003e\u003cp\u003eScientific and clinical-trial information can help readers understand the compound, but it should not be interpreted as a recommendation for individual treatment or as proof that an online product is authentic, safe or legally authorized.\u003c\/p\u003e\u003ch2\u003eMedical \u0026amp; Regulatory Disclaimer\u003c\/h2\u003e\u003cp\u003eThis content is provided for educational and research-information purposes only. Retatrutide remains investigational and should not be represented as an approved UAE medicine.\u003c\/p\u003e\u003cp\u003eThis page does not provide individualized medical advice, dosing instructions, injection instructions or treatment recommendations.\u003c\/p\u003e\u003cp\u003eOnline product availability or pricing does not establish regulatory approval, authenticity, purity, safety or suitability for human use.\u003c\/p\u003e\u003cp\u003eReaders should verify current UAE regulatory requirements and consult a qualified healthcare professional for medical questions.\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e","brand":"Pharma Testostrone","offers":[{"title":"Default Title","offer_id":44629827321944,"sku":null,"price":800.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/Retaklik_Retatrutide_30mg_UAE_research_product.jpg?v=1787244912","url":"https:\/\/timewell.store\/products\/retaklik-retatrutide-30mg-price-uae","provider":"Timewell","version":"1.0","type":"link"}